Innate Pharma (Nasdaq: IPHA) shared important news from Sanofi (Nasdaq: SNY) regarding the U.S. Food and Drug Administration (FDA) granting Fast Track Designation for SAR'579 / IPH6101 to treat hematological malignancies. 

The FDA's Fast Track Designation expedites the development and review of medicines for serious conditions, ensuring potential breakthrough treatments reach patients efficiently. 

Innate Pharma's partnership with Sanofi harnesses their proprietary technology to develop cutting-edge multi-specific antibody formats, engaging NK cells through activating receptors NKp46 and CD16, thereby combating tumor cells. Sanofi assumes responsibility for product development, manufacturing, and commercialization, encompassing IPH6101/SAR'579 and IPH6401/SAR'514. 

The 2016 agreement between the companies offers Innate Pharma potential milestone payments of up to €400 million and royalties on net sales. 

$IPHA is currently trading at $3.21 in pre-market, representing a notable increase of $0.20 (+6.64%).

Hyzon Motors Inc. (Nasdaq: HYZN) has released its first-quarter 2023 financial results, reporting a loss of $0.12 per share, slightly worse than the consensus estimate of a loss of $0.10 per share. 

Despite this, Hyzon Motors' CEO, Parker Meeks, remains optimistic about the company's future endeavors. Meeks outlined key objectives for the remainder of 2023, including the delivery of their inaugural commercial Class 8 FCEV to a prominent U.S. fleet customer, the production and validation of 25 200kW fuel cell system prototypes, and the declaration of the C-sample of their 200kW fuel cell system. 

In pre-market, $HYZN is currently trading at $0.77, up $0.04 (+5.79%).

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)